Austin TX 非小细胞肺癌临床试验
30项针对 非小细胞肺癌的研究正在 Austin及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- New Experimental Therapeutics - NEXT Oncology, Austin
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- NEXT Austin, Austin
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #46, Austin
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- Texas Oncology-Austin Central, Austin
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Texas Oncology - South Austin, Austin
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Texas Oncology- Central South., Austin
- Texas Oncology Central South, Austin
- Texas Oncology- Central South., Austin
- 以及另外 1 项
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Texas Oncology - Central/South Texas, Austin
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Texas Oncology South, Austin
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
招募中1/2 期
- Next Oncology - Austin, Austin
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Texas Oncology (Balcones) - SCRI, Austin
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Local Institution - 007-892-B, Austin
- Local Institution - 007-892-A, Austin
- USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- USO - Texas Oncology, Austin
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology Texas, Austin
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
招募中3 期
- Research Site, Austin
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
招募中1 期
- NEXT Oncology - Austin, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Texas Oncology - Central / South Texas, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- NEXT Oncology Austin /ID# 243005, Austin
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- NEXT Austin, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- NEXT Texas LLC - Austin, Austin
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
招募中1 期
- NEXT Texas LLC - Austin, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
招募中2 期
- Texas Oncology - Austin Central, Austin
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
招募中3 期
- Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- University of Texas at Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 135, Austin
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
招募中2 期
- TxO Central/South, Texas Oncology -Central/South Texas, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
招募中1/2 期
- NEXT Austin, Austin
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY120 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH56 项研究
- Washington, DC55 项研究
Austin的其他研究
- 癌症（所有类型）20 项研究
- 肥胖症20 项研究
- 转移性癌症19 项研究
- 结直肠癌19 项研究
- 心力衰竭18 项研究
- 乳腺癌18 项研究
- 超重18 项研究
- 卵巢癌17 项研究
- 子宫内膜癌15 项研究
- 前列腺癌15 项研究
- 抑郁症14 项研究
- 三阴性乳腺癌13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。